About Schroedinger
Schrödinger is a healthcare-based software company that develops molecular design software for biotech and materials research.
Headquarters
Schroedinger, New York
Founded
1990-08-16
Industry
Biotechnology, Enterprise Software, Pharmaceutical, Software
Last Funding Type
Grant
Valuation
1
Total Funding
$577.22 million dollars
IPO Status
Public
Financial
Schrödinger reported its first quarter 2024 financial results, which missed expectations. Analysts have subsequently reduced their estimates for the company's performance this year. Despite this, there are no significant concerns about the company's cash burn rate.
Schrödinger is advancing in molecular design software, focusing on predicting active compounds and their interactions with biomolecular targets. Their research includes methods for predicting docked positions of ligands in biomolecules, accounting for induced fit effects, and calculating free energy differences between states. These innovations aim to enhance the accuracy of molecular simulations and drug discovery processes, aligning with Schrödinger's expertise in biotech and materials research.
Schrödinger is advancing in molecular design software, focusing on predicting active compounds and their interactions with biomolecular targets. Their research includes methods for predicting docked positions of ligands in biomolecules, accounting for induced fit effects, and calculating free energy differences between states. These innovations aim to enhance the accuracy of molecular simulations and drug discovery processes, aligning with Schrödinger's expertise in biotech and materials research.
Funding Rounds
10
Number of Lead Investors
5
Total Funding Amount
$577.22 million dollars
Number of Investors
16